Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
E2810 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Protocol Number:
NCTNE2810
Phase:
Phase III
Physician:
Jenny Kim
Purpose:
This research is being done to determine whether taking an oral drug known as pazopanib (Votrient®) will reduce the risk of the cancer recurring in the future.
Eligibility:
Generally healthy adults with renal cell carcinoma may be eligible to participate if you: Have no evidence of disease after surgery, Have not received prior chemotherapy, Have normal laboratory results and blood pressure, Have normal ECG results, and Are not pregnant or nursing.
Treatment:
Eligible subjects will receive either pazopanib by mouth each day or a matching placebo (an inactive substance that looks like the study drug, but contains no medication). You will be randomly assigned, like flipping a coin, to either regimen. You or your doctor will not be able to choose the regimen. You will continue to take your assigned study drug for about 1 year. You will have imaging done every 3 months to monitor your disease.
Population:
Adult
Last Update
09/18/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer